CN1298354C - Medicine composition from plant, preparation, use thereof and medicine containing it - Google Patents
Medicine composition from plant, preparation, use thereof and medicine containing it Download PDFInfo
- Publication number
- CN1298354C CN1298354C CNB2004100308606A CN200410030860A CN1298354C CN 1298354 C CN1298354 C CN 1298354C CN B2004100308606 A CNB2004100308606 A CN B2004100308606A CN 200410030860 A CN200410030860 A CN 200410030860A CN 1298354 C CN1298354 C CN 1298354C
- Authority
- CN
- China
- Prior art keywords
- medicine
- seu fructus
- pharmaceutical composition
- calyx seu
- radix scutellariae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 229940079593 drug Drugs 0.000 title claims description 19
- 241000196324 Embryophyta Species 0.000 claims abstract description 18
- 201000007100 Pharyngitis Diseases 0.000 claims abstract description 16
- 208000016150 acute pharyngitis Diseases 0.000 claims abstract description 11
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 10
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 10
- 241001465382 Physalis alkekengi Species 0.000 claims abstract description 6
- 241001164374 Calyx Species 0.000 claims description 29
- 241001106044 Physalis Species 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000000284 extract Substances 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims description 10
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 7
- 241000208292 Solanaceae Species 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 229940046011 buccal tablet Drugs 0.000 claims description 4
- 239000006189 buccal tablet Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000003916 acid precipitation Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 235000008406 SarachaNachtschatten Nutrition 0.000 abstract 1
- 235000004790 Solanum aculeatissimum Nutrition 0.000 abstract 1
- 235000008424 Solanum demissum Nutrition 0.000 abstract 1
- 235000018253 Solanum ferox Nutrition 0.000 abstract 1
- 235000000208 Solanum incanum Nutrition 0.000 abstract 1
- 240000002915 Solanum macrocarpon Species 0.000 abstract 1
- 235000013131 Solanum macrocarpon Nutrition 0.000 abstract 1
- 235000009869 Solanum phureja Nutrition 0.000 abstract 1
- 235000000341 Solanum ptychanthum Nutrition 0.000 abstract 1
- 235000017622 Solanum xanthocarpum Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 230000008961 swelling Effects 0.000 description 11
- 241000712461 unidentified influenza virus Species 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 206010068319 Oropharyngeal pain Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000000114 Pain Threshold Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 230000037040 pain threshold Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 235000009230 Physalis pubescens Nutrition 0.000 description 2
- 235000002491 Physalis viscosa Nutrition 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010030094 Odynophagia Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine composition from plants, and a preparation method and a use thereof and a medicine containing the composition, wherein the plants are nightshade alkekengi Physalisalkekengi and labiate Scutellaria baicalensis, and the medicine is used for treating acute pharyngitis.
Description
Technical field
The present invention relates to derive from pharmaceutical composition and its production and use of plant and the medicine that comprises said composition, wherein this plant origin is plant of Solanaceae Calyx seu fructus physalis (Physalisalkekengi) and labiate Radix Scutellariae (Scutellaria baicalensis), and this medicine is used for the treatment of acute pharyngitis.
Background technology
Acute pharyngitis belongs to the doctor trained in Western medicine acute upper respiratory tract infection, and primary disease all can be fallen ill the whole year, and the winter-spring season pilosity is common clinical, frequently-occurring disease.People can have repeatedly morbidity in 1 year.Acute pharyngitis can be caused by rhinovirus, adenovirus, influenza virus, parainfluenza virus and enterovirus, respiratory syncytial virus etc.; The pathogenic infection person mostly is streptococcal infection.Clinically mainly show as pharyngalgia, odynophagia, dysphagia, pharyngeal drying and heating etc., belong to diseases such as traditional Chinese medical science laryngopharynx swelling and pain, sore throat, swelling throat plug, sore-throat with exogenous febrile diaease, excess-heat in the spleen discomfort in the throat, typhoid fever posterior phraynx inflammation of the throat plug be obstructed.
The Chinese medicine Calyx seu Fructus physalis has another name called Calyx Seu Fructus Physalis, is the dry Constellation calyx of plant of Solanaceae Calyx seu fructus physalis (Physalis alkekengi) or the Constellation calyx of band fruit.Baikal skullcap root is the dry root of labiate Radix Scutellariae (Scutellariabaicalensis).Two prescriptions with or compatibility application of treatment sore throat, laryngopharynx swelling and pain and have sore throat, the record of relevant prescription and case is all arranged at all times.Chinese patent application CN1113794A, CN 1149405A, CN 1255350A, CN 1348788A, CN1377665A, CN 1383883A and CN 1444961A also disclose the herbal mixture of selecting Calyx Seu Fructus Physalis and/or scutellaria for treating laryngopharyngeal diseases for use, but there is not open the two the herbal mixture of Calyx Seu Fructus Physalis and Radix Scutellariae that only contains in these patent documentations fully, the dosage form of more unexposed buccal tablet, and disclosed compound medicines is more because of containing medicament categories in these documents, flavour of a drug are heavier, are not suitable for sucking taking.
Summary of the invention
At the problems of the prior art, the medicine that the invention provides pharmaceutical composition of deriving from plant and its production and use and comprise said composition, wherein this plant origin is plant of Solanaceae Calyx seu fructus physalis (Physalis alkekengi) and labiate Radix Scutellariae (Scutellariabaicalensis), and this medicine is used for the treatment of acute pharyngitis.
Particularly, the present invention relates to:
(1) derive from the pharmaceutical composition of plant, wherein this plant origin is plant of Solanaceae Calyx seu fructus physalis (Physalis alkekengi) and labiate Radix Scutellariae (Scutellaria baicalensis);
(2) according to the pharmaceutical composition of (1), wherein this plant origin is Chinese medicine Calyx seu Fructus physalis and baikal skullcap root;
(3) according to the pharmaceutical composition of (2), be the form of water extract;
(4) as preparation of drug combination method as described in (3), comprise Calyx seu Fructus physalis is made the Calyx seu Fructus physalis extract through water extract-alcohol precipitation, Radix Scutellariae is carried acid precipitation through water make Radix Scutellariae extract, again these two kinds of extracts are mixed;
(5) as the purposes of pharmaceutical composition in medication preparation as described in (1) to (3) any, this medicine is used for the treatment of upper respiratory tract infection;
(6) according to the purposes of (5), wherein this upper respiratory tract infection is acute pharyngitis;
(7) medicine of treatment upper respiratory tract infection comprises any one pharmaceutical composition of basis (1) to (3) as effective ingredient and pharmaceutically acceptable carrier or excipient;
(8) according to the medicine of (7), wherein this upper respiratory tract infection is acute pharyngitis;
(9) according to the medicine of (7) or (8), be the form of oral formulations.
(10) according to the medicine of (9), this oral formulations is tablet, capsule, granule or oral liquid.
(11) according to the medicine of (10), this oral formulations is a buccal tablet.
In the pharmaceutical composition of the present invention, the proportioning of Chinese medicine Calyx seu Fructus physalis and baikal skullcap root (by weight) is 1: 1～10: 1.
Medicine of the present invention has the function of heat-clearing and toxic substances removing, detumescence sore-throat relieving, is mainly used in acute pharyngitis.The rat paw edema that mice ear that medicine xylol of the present invention causes and Ovum Gallus domesticus album cause has the obvious suppression effect; The mice pain reaction threshold value that the thermostimulation of energy significant prolongation causes has significant analgesia role; The influenza virus evidence has the resisiting influenza virus effect; The relevant pathogenic bacterium of upper respiratory tract such as staphylococcus aureus, alpha streptococcus, group B streptococcus all there is tangible antibacterial action.
Use Kunming mouse pharmaceutical composition of the present invention has been carried out acute toxicity test, recording per os LD50 is 16.67 ± 1.06g/kg.
Use the Wistar rat 6 weeks of medicine oral administration of the present invention are carried out long term toxicity test, the result proves that general state, body weight gain and the food utilization of animal is all normal, compares no significant difference with matched group; Hematological indices RBC, WBC+DC, Hb, Pt all in the normal physiological scope, relatively do not have significant difference with matched group; Blood parameters ALT, AST, ALP, BUV, TP, ALB, Glu, Grea, T-CHO, Tbil are all in the normal physiological scope; Organ coefficient and matched group comparison no significant differences such as the heart, liver, spleen, lung, kidney, brain, adrenal gland, testis, uterus; The histopathological examination main organs heart, liver, spleen, lung, kidney, adrenal gland etc. are all no abnormal.
The specific embodiment
Below enumerate embodiment and the pharmacodynamics test example is set forth the present invention in more detail, but never be regarded as restriction invention scope.
Compositions embodiment 1
Calyx Seu Fructus Physalis 250g, Radix Scutellariae 250g are directly pulverized, mix.
Compositions embodiment 2
Calyx Seu Fructus Physalis 1000g, Radix Scutellariae 250g are directly pulverized, mix.
Compositions embodiment 3
Calyx Seu Fructus Physalis 2500g, Radix Scutellariae 250g are directly pulverized, mix.
Compositions embodiment 4
Calyx Seu Fructus Physalis 250g is decocted with water three times, add 25 times of amounts of water at every turn, decocted 2 hours, and merged three times filtrate, filtrate is concentrated into 650ml, promptly be concentrated into every ml medicinal liquid and be equivalent to the 0.4g medical material, add ethanol and make and contain the alcohol amount and reach 70%, precipitate with ethanol 24 hours filters, reclaiming ethanol and being concentrated into proportion is 1.10, and spray drying gets Franchet Groundcherry Fruit 22g; Radix Scutellariae 250g is added in 8 times of amount boiling water, decocted 1.5 hours, filter, medicinal residues decoct with water twice again, add 8 times of amounts of water at every turn, decoct 1.5 hours, merge three times filtrate, filtrate is heated to 70 ℃, transfer to pH 1.5-2.0 with hydrochloric acid, 70 ℃ are incubated 1 hour, leave standstill 24 hours, filter, wash precipitation with water 6.0-6.5 to pH, in 70 ℃ of drying under reduced pressure, pulverize, get Radix Scutellariae extract powder 20g.With Radix Scutellariae extract powder and Calyx Seu Fructus Physalis extract powder mixes, amount to 42g.
Compositions embodiment 5
Calyx Seu Fructus Physalis 1000g is decocted with water three times, add 25 times of amounts of water at every turn, decocted 2 hours, and merged three times filtrate, filtrate is concentrated into 650ml, promptly be concentrated into every ml medicinal liquid and be equivalent to the 1.5g medical material, add ethanol and make and contain the alcohol amount and reach 70%, precipitate with ethanol 24 hours filters, reclaiming ethanol and being concentrated into proportion is 1.10, and spray drying gets Calyx Seu Fructus Physalis extract powder 90g; Radix Scutellariae 250g is added in 8 times of amount boiling water, decocted 1.5 hours, filter, medicinal residues decoct with water twice again, add 8 times of amounts of water at every turn, decoct 1.5 hours, merge three times filtrate, filtrate is heated to 70 ℃, transfer to pH 1.5-2.0 with hydrochloric acid, 70 ℃ are incubated 1 hour, leave standstill 24 hours, filter, wash precipitation with water 6.0-6.5 to pH, in 70 ℃ of drying under reduced pressure, pulverize, get Radix Scutellariae extract powder 20g.The Radix Scutellariae extract powder is mixed with Franchet Groundcherry Fruit, amount to 110g.
Compositions embodiment 6
Calyx Seu Fructus Physalis 2500g is decocted with water three times, add 25 times of amounts of water at every turn, decocted 2 hours, and merged three times filtrate, filtrate is concentrated into 650ml, promptly be concentrated into every ml medicinal liquid and be equivalent to the 4.0g medical material, add ethanol and make and contain the alcohol amount and reach 70%, precipitate with ethanol 24 hours filters, reclaiming ethanol and being concentrated into proportion is 1.10, and spray drying gets Calyx Seu Fructus Physalis extract powder 225g; Radix Scutellariae 250g is added in 8 times of amount boiling water, decocted 1.5 hours, filter, medicinal residues decoct with water twice again, add 8 times of amounts of water at every turn, decoct 1.5 hours, merge three times filtrate, filtrate is heated to 70 ℃, transfer to pH 1.5-2.0 with hydrochloric acid, 70 ℃ are incubated 1 hour, leave standstill 24 hours, filter, wash precipitation with water 6.0-6.5 to pH, in 70 ℃ of drying under reduced pressure, pulverize, get Radix Scutellariae extract powder 20g.With Radix Scutellariae extract powder and Calyx Seu Fructus Physalis extract powder mixes, amount to 245g.
Formulation example 1: capsule
To directly pack in the hard gelatin capsule from the powder of compositions embodiment 1 to 6.
Formulation example 2: buccal tablet
To add 3 times of amount sucrose and make granule from the powder of compositions embodiment 1 to 6, spray into an amount of Mentholum solution, add magnesium stearate, tabletting.
(pharmacodynamics test)
By carrying out following live test, further confirm the effect of medicine of the present invention.Wherein, trial drug is the medicine by the present invention's preparation, and every tablet of medicine contains extract 0.20g; Positive control drug is FUFANG CAOSHANHU HANPIAN (Jiangzhong Pharmaceutical Co., Ltd. produces, lot number 030510).
Antiinflammatory action
1, the influence of the mice ear that causes of xylol
Get 50 of Kunming kind white mice, male and female half and half, body weight 18～22g, divide 5 groups at random, 10 every group, i.e. matched group (with the capacity normal saline), the basic, normal, high dosage group of medicine of the present invention (being respectively 0.25g/kg, 0.5g/kg, 1.0g/kg), FUFANG CAOSHANHU HANPIAN group (0.7g/kg).Adopt gastric infusion, every day 1 time, successive administration 3 days, the last administration is after 45 minutes, embrocate 5 seconds of mouse right ear with dimethylbenzene cotton balls (each 0.05ml), put to death mice after 15 minutes, the mice ears are downcut with the position, with the weighing respectively of JN-D type precision torsion balance with 6mm diameter card punch, with the difference of left and right sides auricle weight as the swelling degree, calculate and respectively to organize swelling degree average and inhibitory rate of intumesce, each administration group and matched group relatively and carry out t and check, the result is as shown in table 1.
The influence of table 1, the swelling of medicine xylol induced mice of the present invention ear
| Group | Dosage (g/kg) | Number of animals (only) | Swelling degree (mg) X ± SD | Suppression ratio (%) | P |
| Matched group | Deng capacity NS | 10 | 11.22±3.78 | - | - |
| The Herba Pileae Scriptae group | 0.7 | 10 | 6.54±2.55 ** | 42 | ＜0.01 |
| Medicine group of the present invention (low) | 0.25 | 10 | 7.07±3.52 * | 37 | ＜0.05 |
| Medicine group of the present invention (in) | 0.50 | 10 | 6.44±3.21 ** | 43 | ＜0.01 |
| Medicine group of the present invention (height) | 1.00 | 10 | 5.34±2.63 ** | 52 | ＜0.01 |
Compare with matched group
*P＜0.05,
*P＜0.01
Basic, normal, high dosage group of medicine of the present invention as can be seen from Table 1 and matched group compare, the difference highly significant, and the ear swelling effect that has obvious suppression dimethylbenzene to cause has certain dose-effect dependence.Its action intensity and Herba Pileae Scriptae are suitable.
2, the influence of the rat paw edema that Ovum Gallus domesticus album is caused
Get 50 of Wistar rats, male and female half and half, body weight 150～180g, be divided into 5 groups at random, every group 10, be matched group (with the capacity normal saline), medicine of the present invention is low, in, high dose group (is respectively 0.17g/kg, 0.34g/kg, 0.68g/kg), FUFANG CAOSHANHU HANPIAN group (0.48g/kg) adopts gastric infusion, once a day, successive administration 3 days, after the last administration 30 minutes, only cause inflammation at each Mus metapedes subcutaneous injection fresh albumen 0.05ml/, with the volumetric method measurement cause scorching before and cause scorching back 1,2,4,6 hours each Mus foot volumes, cause the volumetrical difference of scorching front and back foot as the swelling degree with rat, calculate and respectively organize swelling degree difference average, each administration group and matched group relatively and carry out t check, result of the test is as shown in table 2.
The influence of the rat paw edema that table 2, medicine of the present invention cause Ovum Gallus domesticus album
| Group | Dosage (g/kg) | Number of animals (only) | Cause scorching front foot volume (ml) | Cause scorching back different time paw swelling (ml) X ± SD | |||
| 1 | 2 | 4 | 6(h) | ||||
| Matched group | Deng capacity NS | 10 | 0.26± 0.33 | 2.35± 0.64 | 1.71± 0.41 | 1.50± 0.40 | 1.172± 0.39 |
| The Herba Pileae Scriptae group | 0.48 | 10 | 4.11± 0.26 | 1.75± 0.41 * | 1.11± 0.31 ** | 0.87± 0.42 ** | 0.53± 0.36 ** |
| Medicine of the present invention (low) | 0.17 | 10 | 3.46± 0.27 | 1.74± 0.40 * | 1.02± 0.34 ** | 0.73± 0.46 ** | 0.54± 0.43 ** |
| Medicine of the present invention (in) | 0.34 | 10 | 3.80± 0.51 | 1.40± 0.52 ** | 0.95± 0.47 ** | 0.80± 0.45 ** | 0.37± 0.41 ** |
| Medicine of the present invention (height) | 0.68 | 10 | 3.53± 0.39 | 1.07± 0.44 ** | 0.94± 0.43 ** | 0.61± 0.39 ** | 0.24± 0.32 ** |
Compare with matched group
*P＜0.05,
*P＜0.01
As can be seen from Table 2, basic, normal, high dosage group of medicine of the present invention and matched group compare, and the difference highly significant has the rat paw edema effect that obvious suppression Ovum Gallus domesticus album causes, has certain dosage dependence, and its action intensity is suitable with the Herba Pileae Scriptae group.
The influence (hot plate method) of the white mice pain reaction that thermostimulation is caused
Regulate constant temperature water bath apparatus, make water temperature be controlled at 55 ± 0.5 ℃, after the hot plate preheating 10 minutes, get the female white mice number of body weight 18～22g, place white mice on the hot plate respectively, to lick metapedes, be placed on the hot plate to occurring licking the metapedes required time as this Mus pain threshold from white mice as the pain indicator reaction.Allly lick the metapedes time less than 5 seconds or give it up greater than 30 seconds white mice.Select 50 of qualified mices, divide 5 groups at random, every group 10, be matched group (with the capacity normal saline), the basic, normal, high dosage group of medicine of the present invention (being respectively 0.25g/kg, 0.5g/kg, 1.0g/kg), compound Caoshanhu group (0.7g/kg), adopt gastric infusion, after administration 30 minutes, 45 minutes, surveyed the pain threshold of each Mus in 60 minutes as stated above respectively, the person takes out immediately not lick the metapedes in 60 seconds, its pain threshold calculated by 60 seconds, calculated 30 minutes, 45 minutes, the 60 minutes pain threshold averages of respectively organizing administration.Each administration group and matched group relatively and carry out t check, the result is as shown in table 3.
The influence of the mice pain reaction that table 3, medicine of the present invention cause thermostimulation
| Group | Dosage (g/kg) | Number of animals (only) | The pain response time (second) before the administration | Pain response time (second) X ± SD after the administration | ||
| 30 | 45 | 60 (branches) | ||||
| Matched group | Deng capacity NS | 10 | 17.6±5.2 | 18.3±6.6 | 18.9±6.1 | 19.1±5.7 |
| The Herba Pileae Scriptae group | 0.7 | 10 | 16.5±6.5 | 27.3±5.8 ** | 29.6±6.5 ** | 28.9±5.6 ** |
| Medicine of the present invention (low) | 0.25 | 10 | 17.2±4.8 | 28.7±6.8 ** | 29.8±5.1 ** | 29.1±5.3 ** |
| Medicine of the present invention (in) | 0.50 | 10 | 15.9±5.6 | 30.4±6.4 ** | 32.3±4.6 ** | 31.9±6.5 ** |
| Medicine of the present invention (height) | 1.0 | 10 | 17.9±4.4 | 32.6±5.3 ** | 33.8±6.2 ** | 33.6±5.9 ** |
Compare with matched group
*P＜0.01
As can be seen from Table 3, basic, normal, high dosage group of medicine of the present invention and matched group compare, and difference is very obvious, has apparent in view analgesic activity, and its action intensity is suitable with the effect of compound Caoshanhu group.
Bacteriostasis
Select staphylococcus aureus, alpha streptococcus, group B streptococcus, escherichia coli, Bacillus proteus.Bacteria culture media adopts MH meat soup.Medicine is made letter and is diluted than method, and medicine is managed with MH meat soup dilution 5 row, every row 15.Preceding 13 effective letters than dilution method with drug dilution.Back 2 pipes are cooked the meat soup contrast respectively, the testing tube contrast, and testing tube adds above each bacterium 0.1ml respectively, places 37 ℃ of incubators to cultivate 24 hours, waits for observed result.The result is as shown in table 4.
Table 4, medicine of the present invention are to the inhibitory action of antibacterial
-expression asepsis growth ,+expression has bacteria growing
As can be seen from Table 4, medicine of the present invention is to staphylococcus aureus, alpha streptococcus, and group B streptococcus, escherichia coli, Bacillus proteus have apparent in view inhibitory action.
Result by table 1～table 4 can think that the pharmacodynamics of medicine of the present invention conforms to the function of its heat-clearing and toxic substances removing, reducing swelling and alleviating pain, clearing throat, is a kind of medicine of effective treatment acute pharyngitis.
Antivirus action
Inoculation influenza virus Mus lung adapted strain (A/FM/1/47) is measured the external resisiting influenza virus of medicine of the present invention as virus model on Embryo Gallus domesticus, and the result is as shown in table 5.The result shows that drug effect of the present invention can reduce the appeal of influenza virus in 48 hours, and the result shows that medicine of the present invention has stronger resisiting influenza virus effect.
Table 5, the external resisiting influenza virus effect of medicine of the present invention
| The viral dilution degree | Inoculated into chick embryo number (only) | Infect number (only) | Accumulative total infects number (only) | Infect ratio | Infection rate (%) |
| 10 -1 | 4 | 4 | 32 | 32/32 | 100 |
| 10 -2 | 4 | 4 | 28 | 28/28 | 100 |
| 10 -3 | 4 | 4 | 24 | 24/24 | 100 |
| 10 -4 | 4 | 4 | 20 | 20/20 | 100 |
| 10 -5 | 4 | 4 | 16 | 16/16 | 100 |
| 10 -6 | 4 | 4 | 12 | 12/12 | 100 |
| 10 -7 | 4 | 4 | 8 | 8/8 | 100 |
| 10 -8 | 4 | 4 | 4 | 4/4 | 100 |
| 10 -9 | 4 | 0 | 0 | 0/4 | 0 |
| 10 -10 | 4 | 0 | 0 | 0/8 | 0 |
| 10 -11 | 4 | 0 | 0 | 0/16 | 0 |
| 10 -12 | 4 | 0 | 0 | 0/32 | 0 |
The result shows that drug effect of the present invention can reduce the appeal of influenza virus in 48 hours, shows that medicine of the present invention has stronger resisiting influenza virus effect.
Claims (11)
1, derives from the pharmaceutical composition that is used for the treatment of upper respiratory tract infection of plant, wherein this plant origin is plant of Solanaceae Calyx seu fructus physalis (Physalis alkekengi) and labiate Radix Scutellariae (Scutellaria baicalensis), and the proportioning of Calyx seu fructus physalis and Radix Scutellariae is 1: 1～10: 1 by weight.
2, according to the pharmaceutical composition of claim 1, wherein this plant origin is Chinese medicine Calyx seu Fructus physalis and baikal skullcap root.
3, according to the pharmaceutical composition of claim 2, be the form of water extract.
4, as preparation of drug combination method as described in the claim 3, comprise Calyx seu Fructus physalis is made the Calyx seu Fructus physalis extract through water extract-alcohol precipitation, Radix Scutellariae is carried acid precipitation through water make Radix Scutellariae extract, again these two kinds of extracts are mixed.
5, as the purposes of pharmaceutical composition in medication preparation as described in any one of the claim 1 to 3, this medicine is used for the treatment of upper respiratory tract infection.
6, according to the purposes of claim 5, wherein this upper respiratory tract infection is acute pharyngitis.
7, the medicine of treatment upper respiratory tract infection comprises according to any one pharmaceutical composition of claim 1 to 3 as effective ingredient and pharmaceutically acceptable carrier or excipient.
8, according to the medicine of claim 7, wherein this upper respiratory tract infection is acute pharyngitis.
9, according to the medicine of claim 7 or 8, be the form of oral formulations.
10, according to the medicine of claim 9, this oral formulations is tablet, capsule, granule or oral liquid.
11, according to the medicine of claim 10, this tablet is a buccal tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100308606A CN1298354C (en) | 2004-04-07 | 2004-04-07 | Medicine composition from plant, preparation, use thereof and medicine containing it |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100308606A CN1298354C (en) | 2004-04-07 | 2004-04-07 | Medicine composition from plant, preparation, use thereof and medicine containing it |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1679659A CN1679659A (en) | 2005-10-12 |
| CN1298354C true CN1298354C (en) | 2007-02-07 |
Family
ID=35066665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100308606A Expired - Lifetime CN1298354C (en) | 2004-04-07 | 2004-04-07 | Medicine composition from plant, preparation, use thereof and medicine containing it |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1298354C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101172595B1 (en) * | 2010-05-28 | 2012-08-08 | 김형일 | A composition comprising the extract of Physalis alkekengi var. francheti Masters Hort as an active ingredient for preventing and treating inflammatory disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1072952C (en) * | 1998-12-01 | 2001-10-17 | 胡防言 | Classification and prescriptions for five symptons of chronic pharyngitis |
| CN1136901C (en) * | 2001-11-01 | 2004-02-04 | 王爱丽 | Medicine for treating chronic pharyngitis and its prepn |
-
2004
- 2004-04-07 CN CNB2004100308606A patent/CN1298354C/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1072952C (en) * | 1998-12-01 | 2001-10-17 | 胡防言 | Classification and prescriptions for five symptons of chronic pharyngitis |
| CN1136901C (en) * | 2001-11-01 | 2004-02-04 | 王爱丽 | Medicine for treating chronic pharyngitis and its prepn |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1679659A (en) | 2005-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101836691A (en) | Chinese medicinal herb feed additive | |
| CN101209297A (en) | Compound Chinese medicinal granule for treating chicken coccidiosis | |
| CN101209330A (en) | Compound Chinese medicinal granule with heat-clearing and detoxication, worm-expelling and liver-protecting efficacy | |
| CN102225127B (en) | Traditional Chinese medicine composite for treating mastitis of dairy cattle | |
| CN1772079A (en) | Medicine for treating upper respiratory tract infection and preparation method thereof | |
| CN1425447A (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
| CN1903254B (en) | Compound medicine for treating wind-heat type cold and preparing method thereof | |
| CN101209296A (en) | Chinese medicinal granule with worm-expelling liver-caring, hemostasis and dysentery-stopping efficacy | |
| CN104721337B (en) | Traditional Chinese medicine composition for preventing and treating chicken colibacillosis and preparation method and application thereof | |
| CN1957997A (en) | Animal use compound medicament with effects of relieving the muscles and skin, clearing away heat, relieving darrhea, and relieving dysentery, and preparation method | |
| CN1298354C (en) | Medicine composition from plant, preparation, use thereof and medicine containing it | |
| CN101209304A (en) | Chinese medicinal granule with clearing heat and detoxication, blood-nourishing and dysentery-stopping efficacy | |
| CN109432287B (en) | Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof | |
| CN103142702A (en) | Chinese herbal medicine injection liquid for treating porcine reproductive and respiratory syndrome and preparation method thereof | |
| CN108524746B (en) | Traditional Chinese medicine composition for preventing and treating poultry cold | |
| CN103041120A (en) | Pharmaceutical composition for controlling chicken infectious bursal disease and preparation method thereof | |
| CN1686277A (en) | Medicine for treating child common cold and its preparation method | |
| CN114246894B (en) | Application of Shuangge antidiarrheal oral liquid in preparation of medicine for preventing and treating infectious serositis of duck | |
| TWI740228B (en) | Chinese herbal medicine composition for livestock | |
| CN102078425B (en) | Ephedra-houttuynia cordata oral liquid | |
| CN102614296B (en) | Traditional Chinese medicine composition for preventing and curing respiratory diseases of livestock and application of traditional Chinese medicine composition | |
| CN111588773B (en) | Traditional Chinese medicine composition for preventing and treating newborn piglet diarrhea through sow medicine taking and application thereof | |
| CN115721677B (en) | Traditional Chinese medicine composition for preventing and treating calf bacterial diarrhea, and preparation method and application thereof | |
| CN113813306B (en) | Traditional Chinese medicine composition for preventing and treating infectious rhinitis of chicken | |
| CN111956777A (en) | Traditional Chinese medicine for rapidly abating fever and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine composition from plant, preparation, use thereof and medicine containing it Effective date of registration: 20131219 Granted publication date: 20070207 Pledgee: Shengjing bank Limited by Share Ltd. Shenyang Songling branch Pledgor: Shenyang Tianrui Bio-Tech Development Co.,Ltd. Registration number: 2013210000005 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20151215 Granted publication date: 20070207 Pledgee: Shengjing bank Limited by Share Ltd. Shenyang Songling branch Pledgor: Shenyang Tianrui Bio-Tech Development Co.,Ltd. Registration number: 2013210000005 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine composition from plant, preparation, use thereof and medicine containing it Effective date of registration: 20160129 Granted publication date: 20070207 Pledgee: Shengjing bank Limited by Share Ltd. Shenyang Songling branch Pledgor: Shenyang Tianrui Bio-Tech Development Co.,Ltd. Registration number: 2016210000005 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180208 Granted publication date: 20070207 Pledgee: Shengjing bank Limited by Share Ltd. Shenyang Songling branch Pledgor: Shenyang Tianrui Bio-Tech Development Co.,Ltd. Registration number: 2016210000005 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine composition from plant, preparation, use thereof and medicine containing it Effective date of registration: 20180212 Granted publication date: 20070207 Pledgee: Shengjing bank Limited by Share Ltd. Shenyang Songling branch Pledgor: Shenyang Tianrui Bio-Tech Development Co.,Ltd. Registration number: 2018210000003 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200428 Granted publication date: 20070207 Pledgee: Shengjing bank Limited by Share Ltd. Shenyang Songling branch Pledgor: Shenyang Tianrui Bio-Tech Development Co.,Ltd. Registration number: 2018210000003 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine composition from plant, preparation, use thereof and medicine containing it Effective date of registration: 20200429 Granted publication date: 20070207 Pledgee: Shengjing bank Limited by Share Ltd. Shenyang Songling branch Pledgor: Shenyang Tianrui Bio-Tech Development Co.,Ltd. Registration number: Y2020210000014 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210630 Granted publication date: 20070207 Pledgee: Shengjing bank Limited by Share Ltd. Shenyang Songling branch Pledgor: Shenyang Tianrui Bio-Tech Development Co.,Ltd. Registration number: Y2020210000014 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicinal composition from plant, its preparation method and use, and medicine containing the composition Effective date of registration: 20210701 Granted publication date: 20070207 Pledgee: Shengjing bank Limited by Share Ltd. Shenyang Songling branch Pledgor: Shenyang Tianrui Bio-Tech Development Co.,Ltd. Registration number: Y2021210000042 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070207 |
|
| CX01 | Expiry of patent term |